MENU
IDNA
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IDNA stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM... Show more

Category: #Health
IDNA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IDNA with price predictions
Jul 02, 2026

IDNA in upward trend: price rose above 50-day moving average on June 12, 2026

IDNA moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend. In of 49 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 15, 2026. You may want to consider a long position or call options on IDNA as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IDNA just turned positive on June 12, 2026. Looking at past instances where IDNA's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for IDNA crossed bullishly above the 50-day moving average on June 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 186 cases where IDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IDNA broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares Genomics Immnlgy & Hlthcr ETF ETF is 30.12B. The market cap for tickers in the group ranges from 50.13M to 319.99B. MRK holds the highest valuation in this group at 319.99B. The lowest valued company is SGMO at 50.13M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was 8%. For the same ETF, the average monthly price growth was 22%, and the average quarterly price growth was 34%. MRNA experienced the highest price growth at 13%, while ROG experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was 102%. For the same stocks of the ETF, the average monthly volume growth was 118% and the average quarterly volume growth was 109%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 71
Price Growth Rating: 41
SMR Rating: 82
Profit Risk Rating: 82
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
IDNA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com
IDNA in upward trend: price rose above 50-day moving average on June 12, 2026